← Back to Clinical Trials
Recruiting NCT07047573

NCT07047573 Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07047573
Status Recruiting
Phase
Sponsor Zhao Jun
Condition Lung Cancer (Diagnosis)
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2025-06-01
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2025-06-01 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant nature of pulmonary nodules and the early diagnosis of lung cancer

Eligibility Criteria

Inclusion Criteria: * Patient underwent a ct examination * Patient was confirmed to have pulmonary nodules * Patient has been determined to undergo surgical treatment * There are clear pathological results * The clinicopathological data are complete Exclusion Criteria: * Patient has no ct examination results * Refuse surgical treatment * Patient has no clear pathological diagnosis * Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C. * Patients with tumor emergencies that require immediate treatment. * Poor vascular conditions. * Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy. * Patients with hematogenic infectious diseases, such as HBV. * Patients with psychiatric disorders or severe mental illnesses. * Patients who have difficulty communicating or are unable to be followed up for a long time

Contact & Investigator

Central Contact

Mi Liu

✉ mi.liu831116@icoud.com

📞 86-0512-67972216

Frequently Asked Questions

Who can join the NCT07047573 clinical trial?

This trial is open to participants of all sexes, studying Lung Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07047573 currently recruiting?

Yes, NCT07047573 is actively recruiting participants. Contact the research team at mi.liu831116@icoud.com for enrollment information.

Where is the NCT07047573 trial being conducted?

This trial is being conducted at Suzhou, China.

Who is sponsoring the NCT07047573 clinical trial?

NCT07047573 is sponsored by Zhao Jun. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology